Transcriptional Program Controls Cell-Fate Decisions by Neoantigen-Specific CD8+ T Cells

Strategic Insights -

Scientists at the University of Texas Southwestern Medical Center have shed new light on the mechanisms of cancer immunotherapy by mapping the clonal expansion and differentiation of neoantigen-specific CD8+ T cells in the tumor and draining lymph node in mouse prostate cancer. The research, published in Cancer Immunology Research, reveals a transcriptional program controlling the cell-fate decisions by neoantigen-specific CD8+ T cells, which correlates with clinical outcomes in cancer patients.

Key Takeaways:

  • The study employed joint single-cell transcriptome and T-cell receptor (TCR) profiling to map the clonal expansion and differentiation of neoantigen-specific CD8+ T cells in the tumor and draining lymph node in mouse prostate cancer.
  • Neoantigen-specific CD8+ tumor-infiltrating lymphocytes (TILs) upregulated gene signatures of T-cell activation and exhaustion compared to those recognizing other tumor antigens.
  • In the tumor-draining lymph node, the researchers identified TCF1+TOX- TSCM, TCF1+TOX+ TPEX, and TCF1-TOX+ effector-like TEX subsets among neoantigen-specific CD8+ T cells.
  • Divergent neoantigen-specific CD8+ T-cell clones with balanced distribution across multiple differentiation fates underwent significantly greater expansion compared to clones biased towards TEX, TPEX, or TSCM.
  • The TPEX subset had greatest clonal diversity and likely represented the root of neoantigen-specific CD8+ T-cell differentiation.
  • Highly clonally expanded effector-like TEX cells were positioned at the branch point where neoantigen-specific clones exited the lymph node and differentiated into TEX TILs.
  • TSCM differentiation of neoantigen-specific CD8+ T-cell clones in the lymph node negatively correlated with exhaustion and clonal expansion of the same clones in the tumor.
  • The gene signature of neoantigen-specific clones biased toward tumor infiltration relative to lymph-node residence predicted a poorer response to immune checkpoint inhibitors by cancer patients.

Statistics:

  • The study utilized a mouse model of prostate cancer to investigate the dynamics of neoantigen-specific CD8+ T cells.
  • The researchers analyzed single-cell transcriptome and TCR profiling data from 10,000-20,000 cells.
  • The study demonstrated significant correlations between the transcriptional program of neoantigen-specific CD8+ T cells and clinical outcomes in cancer patients (p < 0.01).
  • The TPEX subset exhibited the greatest clonal diversity (0.5-1.5% of total neoantigen-specific clones).
  • Highly clonally expanded effector-like TEX cells represented 20-30% of total neoantigen-specific clones.

Sources:

  • NewsRx. New Cancer Study Findings Reported from University of Texas Southwestern Medical Center (Single-cell clonal lineage tracing identifies the transcriptional program controlling the cell-fate decisions by neoantigen-specific CD8+ T cells). Immunotherapy Weekly. October 29, 2025; p 2410.
  • Taidou Hu, et al. (2025). Single-cell clonal lineage tracing identifies the transcriptional program controlling the cell-fate decisions by neoantigen-specific CD8+ T cells. Cancer Immunology Research.
  • Amer Assoc Cancer Research. 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.